Overall efforts resulted in several potent ERCC1-XPF endonuclease inhibitors which are capable to diminish NER activity and enhance the cytotoxicity of platinum-based chemotherapeutics although these inhibitors are not explored in targeting DSB repair and its defects for cancer therapy. Here, ERCC1 is linked to cancer.